开发新型的黑激素-伊萨丁混合物作为阿尔茨海默病多功能药物
Ying-Ying Zhong1, Jun-Ze Deng1, Qin Wang2
1School of Pharmacy, Guangdong Medical University, Dongguan, 523808, Guangdong, China.
Molecular diversity
|March 4, 2025
概括
新的黑激素-伊萨丁混合物显示出对阿尔茨海默病 (AD) 治疗的前景. 化合物IM-5和IM-10有效抑制MAO-B,减少粉样β聚合,并保护大脑细胞,改善小鼠的认知能力.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 构成了重大挑战,推动了对新疗法策略的研究.
- 多功能药物越来越多地被探索,以寻找它们在解决AD复杂病理方面的潜力.
- 黑色素和异素支架为药物设计提供了有前途的起点.
研究的目的:
- 设计,合成和评估新型的黑激素-伊萨丁混合物作为AD治疗的多功能药物.
- 评估这些化合物的体外和体内疗效,以对抗AD的主要病理特征.
- 研究化合物的药理动力学和药物相似性.
主要方法:
- 合成美拉-伊萨丁杂交物.
- 在体外测定单胺氧化酶B (MAO-B) 抑制,抗氧化活性 (ORAC-FL) 和氨基酸β (Aβ) 聚合抑制 (ThT测定).
- 在实验室中使用SH-SY5Y细胞进行神经保护测定,并在斯科波胺诱导的认知障碍小鼠模型中进行体内研究.
- 瑞士ADME程序用于药理动力学预测和分子对接以阐明机制.
主要成果:
- 合成的化合物表现出中度到良好的MAO-B抑制和强大的抗氧化活性.
- 化合物IM-5和IM-10显示出最佳的Aβ聚合抑制,IC50值分别为12.4μM和15.6μM对MAO-B.
- IM-5和IM-10表现出低细胞毒性,显著的神经保护,改善了小鼠的记忆障碍,以及有利的类似药物的特性.
结论:
- 氨酸-伊萨丁杂交物,特别是IM-5和IM-10,代表了阿尔茨海默病治疗的有前途的多功能药物.
- 这些化合物有效地向多种AD病理,包括MAO-B活性,Aβ聚合和氧化应激.
- 这些混合物的进一步开发可能会导致阿尔茨海默病的新型治疗干预措施.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.4K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
相关概念视频
01:19Management of Insomnia
182
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
182
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
97
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
97
01:22Alzheimer's Disease: Treatment
125
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
125
01:23Antidepressant Drugs: MAOIs and Other Agents
159
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
159
01:26Alzheimer's Disease: Overview
313
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
313